Use of Biologics in IgE mediated diseases A case based discussion on Omalizumab

Speciality: Emergency Medicine

Description:

 A warm welcome to all the medical professionals in this interesting session on Use of Biologics in IgE mediated diseases A case based discussion on Omalizumab
The use of biologics in treating IgE-mediated diseases has revolutionized the management of conditions like asthma, chronic idiopathic urticaria, and allergic rhinitis. These therapies target specific pathways involved in the allergic response, offering more precise and effective treatment options compared to traditional therapies. Omalizumab, an anti-IgE monoclonal antibody, is a prominent biologic used in these cases.
Omalizumab works by binding to free IgE antibodies in the blood, preventing them from attaching to IgE receptors on mast cells and basophils. This action inhibits the release of inflammatory mediators that cause allergic symptoms. By directly targeting the IgE pathway, omalizumab reduces the frequency and severity of allergic reactions, offering significant relief for patients with severe allergic conditions.
In a case-based discussion, a patient with severe allergic asthma who has not responded to standard treatments can illustrate the effectiveness of omalizumab. After initiating omalizumab therapy, the patient experiences a marked reduction in asthma exacerbations and improved lung function. 
Therefore, get an overall knowledge of use of biologics in IgE mediated diseases A case based discussion on Omalizumab
 

See More Webinars @ Hidoc Webinars